View Filing Data

Nature of Operations [Text Block]

(1) Company Overview

Biota Pharmaceuticals, Inc., together with its wholly owned subsidiaries (“Biota”, or the “Company”) is a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening infectious diseases. The Company has been incorporated in the state of Delaware since 1969 and the corporate headquarters are located in Alpharetta, Georgia. On November 8, 2012, Nabi Biopharmaceuticals (“Nabi”) merged with Biota Holdings Limited, which was previously listed on the Australian Stock Exchange (ASX:BTA), and the resulting company was renamed to Biota Pharmaceuticals, Inc.

The Company currently has two Phase 2 clinical-stage product candidates; laninamivir octanoate, which it is developing under an existing contract with the U.S. Office of Biomedical Advanced Research and Development Authority ("BARDA") to provide up to $231.2 million in financial support to complete the clinical development of laninamivir octanoate for the treatment of influenza A and B infections in the U.S. market; and vapendavir, a potent, oral broad-spectrum capsid inhibitor of enteroviruses including human rhinovirus ("HRV"). In addition, the Company has preclinical programs focused on developing treatments for respiratory syncytial virus ("RSV") as well as for gram-negative and multi-drug resistant bacterial infections.

The Company has developed a neuraminidase inhibitor, zanamivir, which is marketed worldwide by GlaxoSmithKline (“GSK”) as Relenza® for the prevention and treatment of influenza under a research and license agreement entered into with the Company in 1990. In addition, the Company and Daiichi Sankyo Inc. have cross-licensed the world-wide rights to develop and commercialize long-acting neuraminidase inhibitors (“LANI’s”), including laninamivir octanoate, which is marketed by Daiichi Sankyo Inc. as (“Inavir^®” ) in Japan for the treatment of influenza A & B infections in adults and children. In November 2012, Daiichi Sankyo submitted an application for a label change in Japan to manufacture and market the influenza antiviral product Inavir ® for the prevention of influenza infection. The Company has filed an Investigational New Drug application (“IND”) with the United States Food and Drug Administration (“FDA”) to develop laninamivir octanoate, and in 2011 entered into a contract with BARDA designed to provide up to $231.2 million for the completion of the clinical development and U.S. based manufacturing of laninamivir octanoate for the treatment of influenza A and B infections.

Although several of the Company’s influenza products have been successfully developed and commercialized by other larger pharmaceutical companies under license agreements, the Company has not received regulatory approval for any product candidates it has developed independently, and does not have any sales, marketing or commercial capabilities. Therefore, it is possible that the Company may not successfully derive any significant product revenues from any of its existing or future development-stage product candidates.

Merger between Nabi Biopharmaceuticals and Biota Holdings Limited

On November 8, 2012, Nabi and Biota Holdings Limited completed a merger (the “Merger”), and renamed the resulting company Biota Pharmaceuticals, Inc. Former Biota Holdings Limited shareholders retained approximately 83% of the Company’s shares of common stock, while former Nabi shareholders retained approximately 17% as consideration for Nabi’s net assets, the vast majority of which was $27.0 million in net cash on hand on the date of the transaction. As Nabi had minimal ongoing activity with respect to its development programs and related operations at the time of the merger, the Company’s future operations will be largely represented by the operations of Biota Holdings Limited. Further, due to the fact that former Biota Holdings Limited shareholders held a significant majority of the voting interest in the Company upon the completion of the merger, the merger has been accounted for as a “reverse merger”, such that, notwithstanding the fact that Nabi was the legal acquirer, Biota Holdings Limited is considered the accounting acquirer for financial reporting purposes. Accordingly, the financial statements of Biota Holdings Limited are treated as the historical financial statements of the Company, with the operating results of Nabi being included from November 8, 2012. As a result of the reverse merger, the accompanying financial statements share and per share information has been retroactively adjusted to reflect the exchange ratio in the Merger. See Note 3 for additional discussion of the merger.

Note 2 - Basis of Presentation

12 Months Ended

Jun. 30, 2013

Basis of Presentation and Significant Accounting Policies [Text Block]

(2) Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The accompanying consolidated financial statements of Biota Pharmaceuticals, Inc. and its wholly owned subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). All intercompany balances and transactions have been eliminated in consolidation. The Company’s fiscal year ends on June 30.

Use of Estimates

The preparation of the consolidated financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include accruals and obligations, tangible and intangible assets and deferred income taxes. Actual results could differ from those estimates.

Fair Value of Financial Instruments

Financial instruments include cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued liabilities. The carrying amounts of those financial instruments are considered to be representative of their respective fair values because of the short-term nature of those investments.

Cash Equivalents and Short-Term Investments

The Company considers all highly liquid investments with maturities from the date of purchase of three months or less to be cash equivalents. Short-term investments constitute all highly liquid investments with term to maturity from three months to 12 months. The carrying amount of short-term investments is equivalent to its fair value. The Company did not have any short-term investments at June 30, 2013 and June 30, 2012.

Concentration of Credit Risk and Other Risks and Uncertainties

Financial instruments that are exposed to credit risk consist of cash equivalents and accounts receivable. The Company’s cash is deposited with several large commercial banks located in the U.S. and Australia that are federally insured or guaranteed. While balances deposited in these institutions often exceed insured or guaranteed limits, we have not experienced any losses on related accounts to date. If any of these financial institutions or customers fails to perform their obligations under the terms of these financial instruments, the maximum exposure to potential losses would equal amounts reported on the accompanying consolidated balance sheets.

Receivables

Accounts receivable are recorded at the invoiced amount. An allowance for doubtful accounts is estimated based on probable credit losses in the existing accounts receivable. The allowance is determined based on a review of individual accounts for collectability, generally focusing on those that are past due. The current year expense to adjust the allowance for doubtful accounts, if any, is recorded in the consolidated statement of operations. An allowance for uncollectible accounts receivable is estimated based on a combination of default history, aging analysis and any specific, known troubled accounts. When a receivable is finally established as uncollectible, it is written off against the allowance account for accounts receivables.

Property and Equipment

Property and equipment are recorded at acquisition cost, net of accumulated depreciation and impairment. Depreciation on property and equipment is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful life of machinery and equipment is three to 10 years. Leasehold improvements are amortized on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Maintenance and repairs are charged to operations as incurred.

Intangible Assets

Intangible assets generally consist of two elements:

Royalty prepayments

Royalty prepayments represent expenditures made to research institutions where the parties agreed to exchange future variable royalty payments in relation to intellectual property for a fixed payment. These prepayments have a finite useful life, usually being the expiration of the underlying patent or contract, and are carried at the present value of costs at acquisition date, less accumulated amortization. Amortization is based on the anticipated usage of the asset, determined with reference to expected sales of the related product over the contract or patent life.

Computer software

Costs incurred in acquiring software and licenses that are expected to provide future period financial benefits are capitalized to computer software. Amortization is calculated on a straight-line basis over periods ranging from one to three years.

Leased Assets

The Company accounts for its leases at their inception as either an operating or capital lease, depending on certain defined criteria. All of the Company’s leases in effect at June 30, 2013 and June 30, 2012 are considered operating leases. The costs of operating leases are charged to the consolidated statement of operations on a straight-line basis over the lease term. The difference between cash rent payments and straight line rent expense is recorded as deferred rent liability. The balance of deferred rent liabilities is classified in the balance sheet as other liabilities. Additionally, any incentives the Company receives are treated as a reduction of expenses over the term of the agreement. Leasehold improvements by the Company or landlord are capitalized at cost and amortized over the lesser of their expected useful life or the life of the lease, without assuming renewal features, if any, are exercised.

Impairment of Long-lived Assets

The Company reviews its tangible and intangible assets, including patents and licenses, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. In performing an impairment review, the Company estimates undiscounted cash flows from products that are covered by these patents and licenses. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition is less than the carrying amount of the asset. If the evaluation indicates that the carrying value of an asset is not recoverable from its undiscounted cash flows, an impairment loss is measured by comparing the carrying value of the asset to its fair value.

Foreign Currency

Functional and reporting currency

Items included in the Company’s consolidated financial statements are measured using the currency of the primary economic environment in which the entity operates, referred to as the functional currency. The Company operates in several jurisdictions with functional currencies of the U.S. dollar, the Australian dollar, and U.K. Sterling. The consolidated financial statements are presented in U.S. dollars.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the related transactions. Foreign exchange gains and losses resulting from the settlement of such transactions, as well as from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies, are recognized in the consolidated statements of operations.

The results and financial position of any operations that have a functional currency different from the U.S. dollar are translated into U.S. dollar amounts. Assets and liabilities are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at average rates for period.

All resulting exchange differences are recognized as accumulated other comprehensive income, a separate component of stockholders’ equity.

On consolidation, exchange differences arising from the translation of any net investment in foreign entities are recorded in stockholders’ equity as part of accumulated other comprehensive income, net of related taxes.

Patent and License Expense

Legal fees incurred for patent application costs have been charged to expense and reported in research and development expense. Legal fees incurred for patents relating to commercialized products are capitalized and amortized over the life of the patents and reported in research and development expense.

Share-Based Compensation Expense

Share-based compensation expense relates to stock options, restricted stock units or other equity-based grants. The fair market value of stock options is determined at the grant date using an option pricing model based on the closing price of the Company’s common stock on that date. The fair market value of restricted stock units or other equity-based grants are determined at the grant date, based on the closing price of the Company’s common stock on that date. The value of the awards that are ultimately expected to vest is recognized, net of forfeitures, as an expense on a straight-line basis over the employee's requisite service period.

Severance Obligations and Employee Benefits

As a result of the purchase consideration and net assets acquired pursuant to the merger (Note 3) the Company has a $3.0 million liability for severance obligations and employee benefits related to certain key officers and employees. This accrual is classified as a current liability on the consolidated balance sheet.

Income Taxes

The Company applies ASC 740 – Income Taxes, which established financial accounting and reporting requirements for the effects of income taxes that result from the Company’s activities during the current and preceding years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the jurisdictions and years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Where the Company determines that it is more likely than not that some portion or all of the deferred tax assets will not be realized in the future, the deferred tax assets are reduced by a valuation allowance. The valuation allowance is sufficient to reduce the deferred tax assets to the amount that the Company determines is more likely than not to be realized.

Revenue Recognition

Revenue consists primarily of royalty payments, license fees, milestone payments, payments for services performed pursuant to contracts as well as certain research and development activities pursuant to collaborations with other corporate entities.

Revenue for royalties is recognized when the net sales of the underlying product by the relevant third party becomes determinable for the royalty period defined in each agreement. The Company receives communications of the amount of net sales from its licensees’ on a quarterly basis that indicate the amount of royalty revenue for the relevant royalty period. The royalty periods for current license agreements range between one quarter and one year.

Revenue from services performed pursuant to contracts or grants is recognized as revenue when earned, typically when the underlying services or activities are rendered. The Company analyzes cost reimbursable grants and contracts to determine whether it should report such reimbursements as revenue, or as an offset to the related research and development expenses incurred. For costs incurred and revenues generated from third parties where the Company is deemed to be the principal participant, such as the BARDA contract, it recognizes revenue and costs using the gross basis of accounting.

Revenue for collaborative research and development activities typically consists of fees for services, or payments when specific milestones are met and match underlying activities occurring during the term of the arrangement.

For milestones that are deemed substantive, the Company recognizes the contingent revenue when: (i) the milestones have been achieved; (ii) no further performance obligations with respect to the milestones exist; and (iii) collection is reasonably assured. A milestone is considered substantive if all of the following conditions are met: (i) the milestone is non-refundable; (ii) achievement of the milestone was not reasonably assured at the inception of the arrangement; (iii) substantive effort is involved to achieve the milestone; and (iv) the amount of the milestone appears reasonable in relation to the effort expended with the other milestones in the arrangement and the related risk associated with achievement of the milestone. If a milestone is deemed not to be substantive, the Company recognizes the portion of the milestone payment as revenue that correlates to activities already performed; the remaining portion of the milestone payment is deferred and recognized as revenue as the Company completes its performance obligations.

Cost of Revenue

Cost of revenue expense includes, but is not limited to, reimbursement for the cost of third-party service providers incurred in connection with conducting external preclinical studies and treating patients enrolled in clinical trials and monitoring, accumulating and evaluating the related clinical data; salaries and personnel-related expenses for internal staff allocated to a contract, including benefits; and the cost to develop, formulate and manufacture product candidates directly allocated to the specific contract. Cost of Revenue expenses are expensed as incurred.

Research and Development Expense

Research and development expense includes, but is not limited to, the costs of activities associated with: drug discovery, such as medicinal chemistry, virology, microbiology, and biochemistry; drug target discovery, such as molecular biology and structural biology; fees paid to third-party service providers in connection with conducting external preclinical studies and treating patients enrolled in clinical trials and monitoring, accumulating and evaluating the related clinical data; salaries and personnel-related expenses for our internal staff, including benefits and share-based compensation; the cost to develop, formulate and manufacture product candidates; legal fees associated with patents and intellectual property related to our product candidates; research consulting fees; license expenses and sponsored research fees paid to third parties; and specialized information systems, depreciation and laboratory facility costs. Research and development expenses are expensed as incurred.

General and Administrative Expense

General and administrative expense reflects the costs incurred to manage and support our research and development activities. General and administrative expense consists primarily of salaries and personnel-related expenses, including share-based compensation for personnel in executive, finance, accounting, information technology, business development and human resources functions. Other significant costs include professional fees for legal, and auditing, and services, as well as premiums for insurance, other expenses as a result of being publicly-traded, and depreciation and facility expenses.

Total Comprehensive Income

Comprehensive income is defined as the total change in stockholders’ equity during the period other than from transactions with stockholders, and for the Company, includes net income and cumulative translation foreign currency adjustments.

Reclassifications

Certain reclassifications have been made to prior period amounts to conform to the current year presentation.

Recent Accounting Standards

In December 2011, the FASB issued ASU 2011-11, which amended the disclosure requirements regarding offsetting assets and liabilities of derivatives, sale and repurchase agreements, reverse sale and repurchase agreements, and securities borrowing and securities lending arrangements. The enhanced disclosures will require entities to provide both net and gross information for these assets and liabilities. The amendment is effective for fiscal years beginning on or after January 1, 2013. The Company does not anticipate that this amendment will have a material impact on its consolidated financial statements.

In February 2013, the FASB issued ASU No. 2013-02, Comprehensive Income (Topic 220)—Reporting Amounts Reclassified Out of Accumulated Other Comprehensive Income (ASU 2013-02). The ASU adds new disclosure requirements for items reclassified out of accumulated other comprehensive income (“AOCI”) and is intended to help entities improve the transparency of changes in other comprehensive income and items reclassified out of AOCI in their financial statements. The new disclosure requirements became effective for the Company for all interim and annual financial statement reporting periods beginning after December 15, 2012. The adoption of ASU 2013-02 did not change the recognition or measurement of net income or accumulated other comprehensive income.

Note 3 - Merger

12 Months Ended

Jun. 30, 2013

Business Combinations [Abstract]

Business Combination Disclosure [Text Block]

(3) Merger

Summary

On April 22, 2012, Nabi and Biota Holdings Limited entered into a merger implementation agreement (the “Agreement”), which was subsequently amended on August 6, 2012 and further amended on September 17, 2012. On November 8, 2012, Nabi and Biota Holdings Limited completed the merger and pursuant to the terms and subject to the conditions set forth in the Agreement, Biota Holdings Limited became a wholly owned subsidiary of Nabi. As outlined in Note 1, Nabi then changed its name to Biota Pharmaceuticals, Inc.

Reverse Stock Split

On November 8, 2012, as contemplated by the merger and as approved by Nabi’s stockholders and board of directors, Nabi filed a Certificate of Amendment to its Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to affect a reverse stock split of Nabi’s common stock at a ratio of 1:6. As a result of the reverse stock split, each six shares of Nabi common stock issued and outstanding immediately prior to the reverse stock split were automatically combined into and became one share of Nabi common stock. Also, as a result of the reverse stock split, the per share exercise price of, and the number of shares of common stock underlying, the Company outstanding stock options immediately prior to the reverse stock split were automatically proportionally adjusted based on the one-for-six split ratio in accordance with the terms of such options. The reverse stock split did not alter the par value or modify any voting rights or other terms of the common stock.

Merger between Nabi Biopharmaceuticals and Biota Holdings Limited

Upon complication of the merger the resulting company was renamed Biota Pharmaceuticals, Inc. Former Biota Holdings Limited shareholders retained approximately 83% of the Company’s shares of common stock, while former Nabi shareholders retained approximately 17% as consideration for Nabi’s net assets, the vast majority of which was $27.0 million in net cash on hand on the date of the transaction. As Nabi had minimal ongoing activity with respect to its development programs and related operations at the time of the merger, the Company’s future operations will be largely represented by the operations of Biota Holdings Limited. Further, due to the fact that former Biota Holdings Limited shareholders held a significant majority of the voting interest in the Company upon the completion of the merger, the merger has been accounted for as a “reverse merger”, such that, notwithstanding the fact that Nabi was the legal acquirer, Biota Holdings Limited is considered the accounting acquirer for financial reporting purposes. Accordingly, the financial statements of Biota Holdings Limited are treated as the historical financial statements of the Company, with the operating results of Nabi being included from November 8, 2012. As a result of the reverse merger, historical common stock amounts and additional paid-in capital have been adjusted.

Exchange Ratio

Upon completion of the merger, each outstanding share of Biota Holdings Limited common stock converted into the right to receive 0.1249539870 shares of Nabi common stock as determined by the exchange ratio - as calculated pursuant to the terms of the Transaction Agreement, as amended. Pursuant to the various agreements, Biota Holdings Limited stockholders received shares of Nabi common stock representing approximately 83% of the outstanding combined shares of the resulting combined company. Nabi stockholders continued to own their shares of existing Nabi common stock, which represented approximately 17% of the outstanding combined shares of the resulting combined company. The issued share capital upon completion of the merger was comprised of the following:

	No. of Shares
Ex-Nabi stockholders		4,720,999
Ex-Biota Holdings Limited stockholders		23,416,347
Total		28,137,346

Purchase Consideration and Net Assets Acquired

The purchase consideration in a reverse merger is determined with reference to the value of equity that the accounting acquirer (in this case Biota Holdings Limited,) issues to the stockholders of the accounting acquiree (Nabi, in this case) to give them their interest in the combined entity. Further, as a result of the merger, stock options to purchase an aggregate of 0.5 million shares of Nabi common stock that were held by officers and directors of Nabi immediately vested. The fair values of Nabi’s outstanding stock options were determined using the Black-Scholes option pricing model with the following assumptions: a strike price range of $11.34 – $99.91; a volatility range between 78.79% – 99.62%; a risk-free interest rate range of 0.12% – 0.87%; and an expected life range of 0.3 – 6.1 years.

The purchase price, based on the price per share of the Company’s common stock as of the date of the merger is as follows:

Number of shares issued to Nabi stockholders		4,720,999
Fair value per share, using the volume weighted share price on November 9, 2012	$	4.0168
Implied purchase consideration (in millions)	$	19.0

Number of stock options outstanding to former Nabi employees		508,918
Fair value per option	$	0.456
Implied purchase consideration (in millions)	$	0.2

Total implied purchase consideration (in millions)	$	19.2

The net assets acquired as a result of the merger consist of (in millions):

Cash	$	32.7
Accrual for severance obligations and employee benefits		(5.0	)
Accounts payable		(0.7	)
Net cash received	$	27.0

Excess of net assets acquired over total fair value purchase consideration/gain recorded on merger	$	7.8

Due to the significant uncertainty associated with future cash flows from these assets, no purchase consideration has been allocated to the residual value of any of Nabi’s drug development programs, or the potential royalty of Phoslyra that was sold to a third party in 2006.

Pursuant to the Agreement, Biota Holdings Limited received net cash of $27.0 million from Nabi, while Nabi stockholders received a proportion of the combined entity based on the Biota Holdings Limited share price upon completion of the merger. Movements in the Biota Holdings Limited share price and the U.S. and Australian dollar exchange rates between the date of the determination of the exchange ratio and the date of the completion of the merger, coupled with changes in the fair value of certain assets and liabilities, resulted in the net assets acquired exceeding the calculated purchase consideration. The resulting gain of $7.8 million recorded on the completion of the merger is recognized as other income in the consolidated statements of operations.

Acquisition-related Costs

Acquisition-related costs related to the merger, including adviser, investment banking, legal, accounting and various other costs of $4.6 million and $1.9 million have been included as a general and administrative expense for the years ended June 30, 2013 and June 30, 2012, respectively. Total acquisition-related costs were approximately $6.5 million.

Pro forma Financial Information

The following table presents selected unaudited financial information, as if the merger with Nabi had occurred on July 1, 2011 (in millions, except per share data).

	As of June 30,
	2013			2012

Pro forma net revenue	$	34.9		$	23.6
Pro forma net loss		(15.2	)		(24.3	)

Pro forma basic loss per share		(0.54	)		(1.07	)

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6996-128479

+ Details

Note 4 - Financial Instruments

12 Months Ended

Jun. 30, 2013

Financial Instruments Disclosure [Text Block]

(4) Financial Instruments

Financial Assets (in millions)

	As of June 30,
	2013		2012

Financial assets:
Cash and cash equivalents	$	66.8	$	53.8
Accounts receivable		11.0		6.0
Total financial assets		77.8		59.8

Financial liabilities:
Accounts payable		4.4		2.9
Total financial liabilities		4.4		2.9

Net financial assets	$	73.4	$	56.9

The carrying value of the cash and cash equivalents, accounts receivable and accounts payable approximates fair value because of their short-term nature.

The Company regularly reviews all financial assets for impairment. There were no impairments recognized in 2013, 2012 and 2011.

Note 5 - Property and Equipment

12 Months Ended

Jun. 30, 2013

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

(5) Property and Equipment

Property and equipment consist of the following (in millions):

	As of June 30,
	2013			2012

Property and equipment	$	6.3		$	7.0
Leasehold improvements		6.8			7.0

Total Property and equipment		13.1			14.0
Accumulated depreciation		(9.4	)		(9.1	)

Property and equipment, net	$	3.7		$	4.9

Depreciation expense was $1.8 million, $1.8 million and $1.7 million for the fiscal years ended June 30, 2013, 2012 and 2011, respectively.

Note 6 - Intangible Assets

12 Months Ended

Jun. 30, 2013

Intangible Assets Disclosure [Text Block]

(6) Intangible Assets

Intangible assets consist of the following (in millions):

	As of June 30,
	2013			2012

Royalty prepayment	$	12.8		$	14.0
Computer software		1.6			1.6

Total intangible assets		14.4			15.6
Accumulated depreciation		(13.8	)		(13.8	)

Intangible assets, net	$	0.6		$	1.8

Amortization expense was $1.2 million, $1.3 million and $1.3 million for the fiscal years ended June 30, 2013, 2012 and 2011, respectively. As of June 30, 2012, estimated future aggregate amortization expense is $0.5 million and $0.1 million for the years ending June 30, 2014 and 2015, respectively. All future amortization amounts in foreign currencies have been translated at exchange rates as of June 30, 2013 and the remaining amortization period for royalty prepayment is one year.

Note 7 - Accrued and Other Current Liabilities

12 Months Ended

Jun. 30, 2013

Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]

(7) Accrued and Other Current Liabilities

Accrued and other current liabilities consist of the following (in millions):

	As of June 30,
	2013		2012

Legal, tax and accounting fees	$	0.4	$	0.9
Salary and related costs		2.1		2.7
Research and development materials and services		5.4		2.5
Other accrued expenses		0.3		-
Total accrued expenses	$	8.2	$	6.1

Note 8 - Commitments and Contingent Liabilities

12 Months Ended

Jun. 30, 2013

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

(8) Commitments and Contingent Liabilities

Operating Leases

The Company has three main operating leases.

The lease at 2500 Northwinds Parkway is for the Company's headquarters in Alpharetta, Georgia. The lease commenced in April, 2013 and expires in September, 2018. The lease includes an escalating base rent schedule; a seven month rent holiday and a tenant incentive towards leasehold improvements of approximately $0.1 million, which were recognized as a reduction in rent expense on a straight line basis over the term of the lease.

The lease at 585 Blackburn Road, Notting Hill, Victoria, Australia relates to the main Biota laboratories. The lease commenced in September 2004 and was last amended in December 2007. The lease term expires on September 1, 2014 and the Company has the option at that time to extend this lease for a further term of five years at an agreed market rate.

The lease at 597 Blackburn Road, Notting Hill, Victoria, Australia commenced on November 2007 and expired on July 30, 2013. Under the term of the lease, a security deposit of $0.1 million has been paid and has been recorded under “Other Assets” in the Consolidated Balance sheets. In accordance with the terms of the lease, the lessee has to restore the building to its original condition and the lessor can deduct costs from the security cost.

Future minimum lease payments, in millions, under non-cancellable operating leases (with initial or remaining lease terms in excess of one year) as of June 30, 2013 are:

2014	$	0.5
2015		0.3
2016		0.3
2017		0.2
2018		0.1
Thereafter		0.1

Total minimum lease payments	$	1.5

Rent expense was $1.1 million, $0.8 million and $0.8 million for the fiscal years ended June 30, 2013, 2012 and 2011, respectively. The Company also has operating lease agreements for the Oxford, UK offices and office copier equipment under standard terms which are included in the minimum lease payment schedule above.

Government Research Grants

Grant funding is initially recognized as deferred income and released to revenue to match the costs that they are intended to compensate for. Revenue recognized in relation to these grants was $0.6 million, $0.6 million and $2.4 million for the fiscal years ended June 30, 2013, 2012 and 2011, respectively.

In 2006, Biota was awarded a grant of $8.5 million by the National Institute of Allergy and Infectious Diseases, an institute of National Institutes of Health (“NIH”). The award was to develop a class of long-acting neuraminidase inhibitors. This grant was completed in 2011.

In 2011, Biota was awarded a grant of $2.9 million by the NIH. This grant is to fund the Preclinical development of a lead candidate for the treatment of Clostridium Difficile (C diff).

All payments under NIH grants are subject to satisfactory progress and the availability of funding.

Note 9 - Income Taxes

12 Months Ended

Jun. 30, 2013

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

(9) Income Taxes

On November 8, 2012, Nabi and Biota Holdings Limited completed a merger, and renamed the resulting company Biota Pharmaceuticals, Inc. For U.S. federal income tax purposes, the merger was treated as a tax-free transaction with Nabi being treated as the tax acquirer. The merger caused a “change in ownership” of Nabi’s stock under the provisions of Internal Revenue Code (“IRC”) section 382. As a result of the “change in ownership” certain Nabi tax attributes, including net operating losses and tax credits, are subject to limitation pursuant to IRC sections 382 and 383 as discussed below.

The following table includes deferred tax assets and liabilities as of June 30, 2013 and 2012:

	As of June 30,
	2013			2012

Deferred tax assets:
Foreign net operating loss carryforwards	$	18.2		$	21.1
Amortization		0.8			0.9
Depreciation		0.2			0.1
Accrued compensated-related costs		0.4			1.8
Other		3.7			0.4
		23.3			24.3
Deferred tax liabilities:
Royalties		(1.9	)		(1.9	)
		(1.9	)		(1.9	)

Total deferred tax assets		21.4			22.4
Valuation allowance		(21.4	)		(21.1	)

Net deferred tax assets	$	-		$	1.3

Significant components of deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting and tax purposes. As of June 30, 2013 a full valuation allowance has been established, as the Company has determined that the realization of its deferred tax assets is not more likely than not. The Company recorded $21.4 million and $21.1 million of valuation allowance as of June 30, 2013 and 2012, respectively. As of June 30, 2013, the Company has had less than $0.1 million of gross U.S. federal net operating loss carryforwards that expire at various dates through 2033. Under IRC section 382, certain significant changes in ownership may restrict the future utilization of our tax loss carryforwards and tax credit carryforwards. Nabi’s pre-“change in ownership” net operating losses and tax credits are unable to be utilized and are therefore not recorded.

As of June 30, 2013, the Company also has accumulated Australian tax losses of $44.6 million and accumulated United Kingdom tax losses of $23.9 million available for carry forward against future earnings, which under relevant tax laws do not expire but may not be available under certain circumstances.

As of June 30, 2013, the Company’s foreign subsidiaries have no positive accumulated earnings. As such, no federal or state income taxes have been provided on the losses of its foreign subsidiaries under ASC 740. If in the future there are positive earnings generated from the Company’s foreign subsidiaries, the Company will evaluate whether to record any applicable federal and state income taxes on such earnings.

For financial reporting purposes, income before taxes includes the following components:

	Years Ended June 30,
	2013			2012			2011

United States	$	6.7		$	-		$	-
Foreign		(15.3	)		(19.7	)		(26.1	)

Total	$	(8.6	)	$	(19.7	)	$	(26.1	)

The expense (benefit) for income taxes is comprised of:

	Years Ended June 30,
	2013		2012			2011
Current:
Federal	$	-	$	-		$	-
State		-		-			-
Foreign		0.1		(0.3	)		(1.2	)
		0.1		(0.3	)		(1.2	)
Deferred:
Federal		-		-			-
State		-		-			-
Foreign		-		(0.2	)		0.4
		-		(0.2	)		0.4
Total Tax Expense	$	0.1	$	(0.5	)	$	(0.8	)

The reconciliation between the company's effective tax rate and the statutory rate is as follows:

	Years Ended June 30,
	2013			2012			2011
Income tax expense (benefit) at federal statutory rate	$	(3.3	)	$	(6.9	)	$	(9.2	)
State and local income taxes, net of federal benefit		0.3			-			-
Foreign tax rate differential		1.3			0.9			0.5
Change in valuation allowance (Net of Nabi merger)		4.2			2.8			9.8
Gain on merger		(3.0	)		-			-
Research and development expenses		1.1			2.9			(1.3	)
Research and development tax credits		(1.1	)		(0.3	)		(1.1	)
Employee stock options		0.5			0.2			0.1
Other		0.1			(0.1	)		0.4
Income tax expense (benefit)	$	0.1		$	(0.5	)	$	(0.8	)

Uncertain Tax Positions

The Company is subject to income taxes in the U.S., various states, Australia, and the United Kingdom. Significant judgment is required in evaluating the Company’s tax positions and determining the provision for income taxes. The Company has established reserves for tax-related uncertainties based on estimates of whether, and to the extent to which, additional taxes may be due. These reserves are established when the Company believes that certain positions might be challenged despite its belief that its tax return positions are fully supportable. The Company adjusts these reserves in light of changing facts and circumstances, such as the outcome of a tax audit.

The Company is subject to tax audits in all jurisdictions for which it files tax returns. Tax audits by their very nature are often complex and can require several years to complete. Under the tax statute of limitations application to the IRC, the Company is no longer subject to U.S. federal income tax examinations by the Internal Revenue Services (“IRS”) for years before 2010. Under the statute of limitations applicable to most state income tax laws, the Company is no longer subject to state income tax examinations by tax authorities for years before 2009 in states in which we have filed income tax returns. Certain states may take the position that the Company is subject to income tax in such states even though the Company has not filed income tax returns in such states and, depending on the varying state income tax statutes and administrative practices, the statute of limitations in such states may extend to years before 2009. The Company began foreign operations in 1985. The Company is subject to foreign tax examinations by tax authorities for all years of operations.

The Company does not have any unrecognized tax benefits as of June 30, 2013.

Note 10 - Share Based Compensation

12 Months Ended

Jun. 30, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

(10) Share-Based Compensation

A summary of stock options outstanding as of June 30, 2013, and the related activity during the year ended June 30, 2013, is presented below.

	Number of Options
Options	Biota Holdings Limited			Nabi			Biota Pharmaceuticals, Inc.

Outstanding at June 30, 2012		6,182,853			3,665,201			-
Granted		686,365			-			-
Exercised		(413,335	)		-			-
Forfeited		-			(20,000	)		-
Expired		(601	)		(591,485	)		-

		6,455,282			3,053,716			-
Adjustment for Consolidation of shares					(2,544,798	)		-
Vested and exercised upon merger		(6,455,282	)		-			-
Balance on November 8, 2012 (date of merger)		-			508,918			-

Post-merger transactions:
Granted		-			-			1,166,590
Expired		-			(16,979	)		-

Outstanding at June 30, 2013		-			491,939			1,166,590

Exercisable at June 30, 2013		-			491,939			-

On November 8, 2012, and in connection with the merger and based upon stockholder approval, Nabi’s board of directors approved a 1:6 reverse stock split of existing Nabi shares, which reduced the number of shares of common stock reserved for outstanding stock options to 508,918. The exercise price of all outstanding stock options as of that date have been adjusted to reflect the reverse stock split and are now between $11.22 and $99.94 per share, with terms expiring from March, 2014 to January, 2019.

Biota Holdings Limited had outstanding stock options to purchase 6,455,282 shares of its common stock at September 30, 2012. Upon approval of the merger with Nabi by the Supreme Court of Victoria on October 26, 2012, all of these outstanding stock options vested, resulting in the issuance of 4,639,104 shares of common stock and the vesting of 1,816,178 shares held by Biota Holdings Limited for this purpose. The related expense of $1.1 million associated with the issuance of shares of common stock has been recognized as a general and administrative expense in the consolidated statement of operations of Biota Holdings Limited.

During the year ended June 30, 2013, the Company granted, and the Board of Directors approved, stock options to purchase a total of 1,166,590 shares of common stock. Of this total, 1,076,590 stock options were granted to employees at exercise prices between $3.14 and $4.07. The employee grants are exercisable from one to four years from the date of the grant and have a 10 year term. The Company granted 30,000 stock options to existing Board of Directors members at an exercise price of $4.05, exercisable one year from the date of grant with a six year term and 60,000 stock options to new Board of Directors members at an exercise price of $4.05, exercisable from one to three years from the date of grant with a 10 year term.

The weighted average fair value of awards granted during the year ended June 30, 2013 was estimated to be $2.39. The Company estimated the fair value of each stock option on the date of grant, using the Black-Scholes option-pricing formula, using the following key assumptions:

Expected Term: The expected term represents the period over which the share-based awards are expected to be outstanding, giving consideration to the expectations of future employee behavior, the contractual terms of the share-based awards and vesting conditions, option price and stock price. The Company estimates an expected term of six years for employee option grants, four years for existing director grants and five years for new director grants.

Risk-Free Interest Rate: The Company used risk-free rates between 0.30% and 0.60%, based upon the risk-free interest rate used in the assumptions on the implied yield currently available on the U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of the stock option award.

Expected volatility: The Company used an expected volatility factor of 79.12%, based on the historical price of its common stock over the most recent period commensurate with the expected term of the stock option award.

Expected Dividend Yield: The Company does not intend to pay any cash dividends on common stock for the foreseeable future. Accordingly, it assumed a dividend yield of zero.

Expected Forfeitures: The total number of stock option awards expected to vest is adjusted by estimated forfeiture rates. The Company estimated the expected forfeiture rate to be 5.0% based on actual and anticipated forfeitures.

The Company amortizes share-based compensation expense over the option’s vesting period using the straight-line attribution approach. For the year ended June 30, 2013, the Company recognized approximately $0.5 million of share-based compensation expense related to the issuance of stock option grants.

A summary of outstanding restricted stock awards as of June 30, 2013, and the related activity during the year ending June 30, 2013 is presented below:

	Number of Awards
Awards	Nabi			Biota Pharmaceuticals, Inc.

Unvested at June 30, 2012		196,254			-
Vested and shares issued		(196,254	)		-

Balance on November 8, 2012 (date of merger)		-			-

Post-merger transactions:
Granted		-			241,083
Vested		-			(71,661	)

Outstanding at June 30, 2013	Nil				169,422

On November 12, 2012, the Company granted 214,983 units of restricted stock awards with an average fair value of $4.07. The restricted shares vest over three equal installments: upon 90 days, and on the first and second anniversaries of the grant date. On May 1, 2013, the Company granted 26,100 of restricted stock units with an average fair value of $4.05 and vest one year from the date of grant. For the year ended June 30, 2013, the Company recognized approximately $0.5 million of share-based compensation expense related to the issuance of restricted stock units.

At June 30, 2013, there was $2.3 million of unrecognized compensation expense related to unvested share-based compensation arrangements. The weighted-average period over which this expense is expected to be recognized is 2.6 years.

Note 11 - Retirement Benefits

12 Months Ended

Jun. 30, 2013

Compensation and Retirement Disclosure [Abstract]

Pension and Other Postretirement Benefits Disclosure [Text Block]

(11) Retirement Benefits

The Company contributed $1.1 million, $1.1 million and $1.0 million for the fiscal years ended June 30, 2013, 2012 and 2011, respectively, toward standard defined contribution plans for employees. Contributions by the Company for non-U.S. employees can be up to nine per cent of employee salary during fiscal year ending June 30, 2013 and up to four per cent of employee salary for U.S. employees.

Note 12 - Net Loss Per Share

12 Months Ended

Jun. 30, 2013

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

(12) Net Loss per Share

Basic and diluted loss per share has been computed based on net loss and the weighted-average number of common shares outstanding during the applicable period. For diluted net loss per share, common stock equivalents (shares of common stock issuable upon the exercise of stock options and warrants) are excluded from the calculation of diluted net loss per share as their inclusion would be anti-dilutive. The Company has excluded all stock options to purchase common stock in periods indicating a loss, as their effect is anti-dilutive.

The following table sets forth the computation of historical basic and diluted net loss per share.

	Year Ended June 30,
	2013			2012			2011

Net loss (in millions)	$	(8.7	)	$	(19.2	)	$	(25.4	)
Weighted-average shares outstanding		28,217,515			181,775,444			180,610,151
Weighted- average shares outstanding adjusted using exchange ratio used to compute basic earnings per share		-			22,713,566			22,567,958
Shares used to compute diluted earnings per share		28,217,515			22,713,566			22,567,958
Basic loss per share	$	(0.31	)	$	(0.85	)	$	(1.12	)
Diluted loss per share	$	(0.31	)	$	(0.85	)	$	(1.12	)
Number of antidilutive stock options excluded from computation		-			-			1,658,529

Note 13 - Research and Development Credit

12 Months Ended

Jun. 30, 2013

Research and Development [Abstract]

Research, Development, and Computer Software Disclosure [Text Block]

(13) Research and Development Credit

An application for a claim of $4.4 million was made by the Company’s subsidiary, Biota Holdings Limited, under the Australian Government’s Research and Development tax incentive when Biota Holdings Limited submitted its tax return for its fiscal year ended June 30, 2012. This amount was recorded as a contingent asset as of June 30, 2012. On November 7, 2012, Biota Holdings Limited received cash for this claim. Although the credit is administered by the Australian government, it is not linked to the level of taxable income and is effectively a government grant. As such, the Company obtained an immediate benefit and therefore, the entire amount has been recognized within non-operating income in the consolidated statement of operations for the year ending June 30, 2013.

For the current fiscal year, the Company does not expect to receive a research and development credit as its revenue is expected to exceed the qualifying revenue threshold.

Organization, Consolidation and Presentation of Financial Statements [Abstract]

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References + Details

Note 14 - Licences, Royalty Collaborative and Contractual Arrangements

12 Months Ended

Jun. 30, 2013

Collaborative Arrangement Disclosure [Text Block]

(14) Licenses, Royalty Collaborative and Contractual Arrangements

Royalty agreements

The Company entered into a royalty-bearing research and license agreement with GSK in 1990 for the development and commercialization of zanamivir, a neuraminidase inhibitor (“NI”) marketed by GSK as Relenza^® to treat influenza. Under the terms of the agreement, the Company licensed zanamivir to GSK on an exclusive, worldwide basis and is entitled to receive royalty payments of 7% of GSK's annual net sales of Relenza^® in the U.S., Europe, Japan and certain other countries as well as 10% of GSK's annual net sales of Relenza^® in Australia, New Zealand, South Africa and Indonesia. Beginning in 2014, the patents on Relenza^® are scheduled to expire in certain countries and are scheduled to fully expire in 2019.

The Company also generates royalty revenue from the sale of Inavir^® in Japan, pursuant to a collaboration and license agreement that the Company entered into with Daiichi Sankyo in 2009. In September 2010, laninamivir octanoate was approved for sale by the Japanese Ministry of Health and Welfare for the treatment of influenza in adults and children, which Daiichi Sankyo markets as Inavir^®. Under the agreement, the Company currently receives a 4% royalty on net sales of Inavir^® in Japan and is eligible to earn sales milestone payments. Under the collaboration and license agreement, the Company and Daiichi Sankyo have cross-licensed the world-wide rights to develop and commercialize the related intellectual property, and have agreed to share equally in any royalties, license fees, or milestone or other payments received from any third party licenses outside of Japan. Patents on laninamivir octanoate in Japan generally expire in 2024.

Collaborative and contract arrangements

On March 31, 2011, the Company’s wholly owned subsidiary, Biota Scientific Management Pty Ltd., was awarded a contract by BARDA for the late-stage development of laninamivir octanoate on a cost-plus-fixed-fee basis, the total of which is not to exceed $231.2 million. BARDA is part of the U.S. Office of the Assistant Secretary for Preparedness and Response ("ASPR") within the U.S. Department of Health and Human Services ("HHS"). The BARDA contract is designed to fund and provide the Company with all technical and clinical data, and U.S. based manufacturing, to support the filing of a U.S. new drug application (“NDA”) with the FDA for laninamivir octanoate. The performance period of the BARDA contract commenced on March 31, 2011, and continues for five years.

The Company is considered an active participant in the BARDA contract, with exposure to significant risks and rewards of commercialization relating to the development of laninamivir octanoate. Therefore, revenues from and costs associated with the contract are recorded and recognized on a gross basis in the consolidated statement of operations. Revenue totaling $34.1 million has been recognized to-date pursuant to this contract.

Changes in government policies, priorities or funding levels through agency or program budget reductions by the U.S. Congress or executive agencies could materially adversely affect the Company’s financial condition or results of operations if such changes negatively impacted our contract with BARDA. Furthermore, contracts with the U.S. government may be terminated or suspended by the U.S. government at any time, with or without cause. Such contract suspensions or terminations could result in expenses or charges not being reimbursed, or otherwise adversely affect the Company’s financial condition and/or results of operations.

The following tables summarize the key components of the Company’s revenues (in millions):

	Years Ended June 30,
	2013		2012		2011
Royalty revenue – Relenza^®	$	2.6	$	4.4	$	6.6
– Inavir^®		4.2		4.5		2.9
Commercial milestone – Inavir^®		2.8		-		-
Revenue from services		24.0		11.5		3.0
Total revenue	$	33.6	$	20.4	$	12.5

Note 15 - Quarterly Financial Information (Unaudited)

12 Months Ended

Jun. 30, 2013

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Information [Text Block]

(15) Quarterly Financial Information (Unaudited)

The table below sets forth summary unaudited consolidated quarterly financial information for the years ended June 30, 2013 and 2012 (in millions):

	Quarter Ended
	6/30/2013			3/31/2013		12/31/2012		9/30/2012
Revenues	$	9.3		$	12.5	$	10.4	$	1.4
Operating expenses		7.7			4.1		7.1		1.5
Net (loss) income		(6.5	)		0.2		4.8		(7.2	)
Net (loss) income per share (1):
Basic	$	(0.23	)	$	0.01	$	0.17	$	(0.32	)
Diluted	$	(0.23	)	$	0.01	$	0.17	$	(0.32	)

	Quarter Ended
	6/30/2012			3/31/2012			12/31/2011			9/30/2011
Revenues	$	7.1		$	7.1		$	2.1		$	4.1
Operating expenses		3.8			1.8			2.9			1.4
Net loss		(5.9	)		(2.0	)		(7.1	)		(4.2	)
Net loss per share (1):
Basic	$	(0.26	)	$	(0.09	)	$	(0.31	)	$	(0.18	)
Diluted	$	(0.26	)	$	(0.09	)	$	(0.31	)	$	(0.18	)

)

Due to the use of the weighted average shares outstanding for each quarter for computing earnings per share, the sum of the quarterly per share amounts may not equal the per share amount for the year.

Accounting Policies, by Policy (Policies)	12 Months Ended
Accounting Policies, by Policy (Policies)	Jun. 30, 2013
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	*Basis of Presentation and Principles of Consolidation* The accompanying consolidated financial statements of Biota Pharmaceuticals, Inc. and its wholly owned subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). All intercompany balances and transactions have been eliminated in consolidation. The Company’s fiscal year ends on June 30.
Use of Estimates, Policy [Policy Text Block]	*Use of Estimates* The preparation of the consolidated financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include accruals and obligations, tangible and intangible assets and deferred income taxes. Actual results could differ from those estimates.
Fair Value of Financial Instruments, Policy [Policy Text Block]	*Fair Value of Financial Instruments* Financial instruments include cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued liabilities. The carrying amounts of those financial instruments are considered to be representative of their respective fair values because of the short-term nature of those investments.
Cash and Cash Equivalents, Policy [Policy Text Block]	*Cash Equivalents and Short-Term Investments* The Company considers all highly liquid investments with maturities from the date of purchase of three months or less to be cash equivalents. Short-term investments constitute all highly liquid investments with term to maturity from three months to 12 months. The carrying amount of short-term investments is equivalent to its fair value. The Company did not have any short-term investments at June 30, 2013 and June 30, 2012.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	*Concentration of Credit Risk and Other Risks and Uncertainties* Financial instruments that are exposed to credit risk consist of cash equivalents and accounts receivable. The Company’s cash is deposited with several large commercial banks located in the U.S. and Australia that are federally insured or guaranteed. While balances deposited in these institutions often exceed insured or guaranteed limits, we have not experienced any losses on related accounts to date. If any of these financial institutions or customers fails to perform their obligations under the terms of these financial instruments, the maximum exposure to potential losses would equal amounts reported on the accompanying consolidated balance sheets.
Receivables, Policy [Policy Text Block]	*Receivables* Accounts receivable are recorded at the invoiced amount. An allowance for doubtful accounts is estimated based on probable credit losses in the existing accounts receivable. The allowance is determined based on a review of individual accounts for collectability, generally focusing on those that are past due. The current year expense to adjust the allowance for doubtful accounts, if any, is recorded in the consolidated statement of operations. An allowance for uncollectible accounts receivable is estimated based on a combination of default history, aging analysis and any specific, known troubled accounts. When a receivable is finally established as uncollectible, it is written off against the allowance account for accounts receivables.
Property, Plant and Equipment, Policy [Policy Text Block]	*Property and Equipment* Property and equipment are recorded at acquisition cost, net of accumulated depreciation and impairment. Depreciation on property and equipment is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful life of machinery and equipment is three to 10 years. Leasehold improvements are amortized on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Maintenance and repairs are charged to operations as incurred.
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	*Assets* Intangible assets generally consist of two elements: Royalty prepayments Royalty prepayments represent expenditures made to research institutions where the parties agreed to exchange future variable royalty payments in relation to intellectual property for a fixed payment. These prepayments have a finite useful life, usually being the expiration of the underlying patent or contract, and are carried at the present value of costs at acquisition date, less accumulated amortization. Amortization is based on the anticipated usage of the asset, determined with reference to expected sales of the related product over the contract or patent life. Computer software Costs incurred in acquiring software and licenses that are expected to provide future period financial benefits are capitalized to computer software. Amortization is calculated on a straight-line basis over periods ranging from one to three years.
Lease, Policy [Policy Text Block]	*Leased Assets* The Company accounts for its leases at their inception as either an operating or capital lease, depending on certain defined criteria. All of the Company’s leases in effect at June 30, 2013 and June 30, 2012 are considered operating leases. The costs of operating leases are charged to the consolidated statement of operations on a straight-line basis over the lease term. The difference between cash rent payments and straight line rent expense is recorded as deferred rent liability. The balance of deferred rent liabilities is classified in the balance sheet as other liabilities. Additionally, any incentives the Company receives are treated as a reduction of expenses over the term of the agreement. Leasehold improvements by the Company or landlord are capitalized at cost and amortized over the lesser of their expected useful life or the life of the lease, without assuming renewal features, if any, are exercised.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	*Impairment of Long-lived Assets* The Company reviews its tangible and intangible assets, including patents and licenses, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. In performing an impairment review, the Company estimates undiscounted cash flows from products that are covered by these patents and licenses. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition is less than the carrying amount of the asset. If the evaluation indicates that the carrying value of an asset is not recoverable from its undiscounted cash flows, an impairment loss is measured by comparing the carrying value of the asset to its fair value.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	*Foreign Currency* Functional and reporting currency Items included in the Company’s consolidated financial statements are measured using the currency of the primary economic environment in which the entity operates, referred to as the functional currency. The Company operates in several jurisdictions with functional currencies of the U.S. dollar, the Australian dollar, and U.K. Sterling. The consolidated financial statements are presented in U.S. dollars. Transactions and balances Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the related transactions. Foreign exchange gains and losses resulting from the settlement of such transactions, as well as from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies, are recognized in the consolidated statements of operations. The results and financial position of any operations that have a functional currency different from the U.S. dollar are translated into U.S. dollar amounts. Assets and liabilities are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at average rates for period. All resulting exchange differences are recognized as accumulated other comprehensive income, a separate component of stockholders’ equity. On consolidation, exchange differences arising from the translation of any net investment in foreign entities are recorded in stockholders’ equity as part of accumulated other comprehensive income, net of related taxes.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	*Patent and License Expense* Legal fees incurred for patent application costs have been charged to expense and reported in research and development expense. Legal fees incurred for patents relating to commercialized products are capitalized and amortized over the life of the patents and reported in research and development expense.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	*Share-Based Compensation Expense* Share-based compensation expense relates to stock options, restricted stock units or other equity-based grants. The fair market value of stock options is determined at the grant date using an option pricing model based on the closing price of the Company’s common stock on that date. The fair market value of restricted stock units or other equity-based grants are determined at the grant date, based on the closing price of the Company’s common stock on that date. The value of the awards that are ultimately expected to vest is recognized, net of forfeitures, as an expense on a straight-line basis over the employee's requisite service period.
Severance Obligations and Employee Benefits [Policy Text Block]	Severance Obligations and Employee BenefitsAs a result of the purchase consideration and net assets acquired pursuant to the merger (Note 3) the Company has a $3.0 million liability for severance obligations and employee benefits related to certain key officers and employees. This accrual is classified as a current liability on the consolidated balance sheet.
Income Tax, Policy [Policy Text Block]	*Income Taxes* The Company applies ASC 740 – Income Taxes, which established financial accounting and reporting requirements for the effects of income taxes that result from the Company’s activities during the current and preceding years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the jurisdictions and years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Where the Company determines that it is more likely than not that some portion or all of the deferred tax assets will not be realized in the future, the deferred tax assets are reduced by a valuation allowance. The valuation allowance is sufficient to reduce the deferred tax assets to the amount that the Company determines is more likely than not to be realized.
Revenue Recognition, Policy [Policy Text Block]	*Revenue Recognition* Revenue consists primarily of royalty payments, license fees, milestone payments, payments for services performed pursuant to contracts as well as certain research and development activities pursuant to collaborations with other corporate entities. Revenue for royalties is recognized when the net sales of the underlying product by the relevant third party becomes determinable for the royalty period defined in each agreement. The Company receives communications of the amount of net sales from its licensees’ on a quarterly basis that indicate the amount of royalty revenue for the relevant royalty period. The royalty periods for current license agreements range between one quarter and one year. Revenue from services performed pursuant to contracts or grants is recognized as revenue when earned, typically when the underlying services or activities are rendered. The Company analyzes cost reimbursable grants and contracts to determine whether it should report such reimbursements as revenue, or as an offset to the related research and development expenses incurred. For costs incurred and revenues generated from third parties where the Company is deemed to be the principal participant, such as the BARDA contract, it recognizes revenue and costs using the gross basis of accounting. Revenue for collaborative research and development activities typically consists of fees for services, or payments when specific milestones are met and match underlying activities occurring during the term of the arrangement. For milestones that are deemed substantive, the Company recognizes the contingent revenue when: (i) the milestones have been achieved; (ii) no further performance obligations with respect to the milestones exist; and (iii) collection is reasonably assured. A milestone is considered substantive if all of the following conditions are met: (i) the milestone is non-refundable; (ii) achievement of the milestone was not reasonably assured at the inception of the arrangement; (iii) substantive effort is involved to achieve the milestone; and (iv) the amount of the milestone appears reasonable in relation to the effort expended with the other milestones in the arrangement and the related risk associated with achievement of the milestone. If a milestone is deemed not to be substantive, the Company recognizes the portion of the milestone payment as revenue that correlates to activities already performed; the remaining portion of the milestone payment is deferred and recognized as revenue as the Company completes its performance obligations.
Cost of Sales, Policy [Policy Text Block]	*Cost of Revenue* Cost of revenue expense includes, but is not limited to, reimbursement for the cost of third-party service providers incurred in connection with conducting external preclinical studies and treating patients enrolled in clinical trials and monitoring, accumulating and evaluating the related clinical data; salaries and personnel-related expenses for internal staff allocated to a contract, including benefits; and the cost to develop, formulate and manufacture product candidates directly allocated to the specific contract. Cost of Revenue expenses are expensed as incurred.
Research and Development Expense, Policy [Policy Text Block]	*Research and Development Expense* Research and development expense includes, but is not limited to, the costs of activities associated with: drug discovery, such as medicinal chemistry, virology, microbiology, and biochemistry; drug target discovery, such as molecular biology and structural biology; fees paid to third-party service providers in connection with conducting external preclinical studies and treating patients enrolled in clinical trials and monitoring, accumulating and evaluating the related clinical data; salaries and personnel-related expenses for our internal staff, including benefits and share-based compensation; the cost to develop, formulate and manufacture product candidates; legal fees associated with patents and intellectual property related to our product candidates; research consulting fees; license expenses and sponsored research fees paid to third parties; and specialized information systems, depreciation and laboratory facility costs. Research and development expenses are expensed as incurred.
Selling, General and Administrative Expenses, Policy [Policy Text Block]	*General and Administrative Expense* General and administrative expense reflects the costs incurred to manage and support our research and development activities. General and administrative expense consists primarily of salaries and personnel-related expenses, including share-based compensation for personnel in executive, finance, accounting, information technology, business development and human resources functions. Other significant costs include professional fees for legal, and auditing, and services, as well as premiums for insurance, other expenses as a result of being publicly-traded, and depreciation and facility expenses.
Comprehensive Income, Policy [Policy Text Block]	*Total Comprehensive Income* Comprehensive income is defined as the total change in stockholders’ equity during the period other than from transactions with stockholders, and for the Company, includes net income and cumulative translation foreign currency adjustments.
Reclassification, Policy [Policy Text Block]	*Reclassifications* Certain reclassifications have been made to prior period amounts to conform to the current year presentation.
New Accounting Pronouncements, Policy [Policy Text Block]	*Recent Accounting Standards* In December 2011, the FASB issued ASU 2011-11, which amended the disclosure requirements regarding offsetting assets and liabilities of derivatives, sale and repurchase agreements, reverse sale and repurchase agreements, and securities borrowing and securities lending arrangements. The enhanced disclosures will require entities to provide both net and gross information for these assets and liabilities. The amendment is effective for fiscal years beginning on or after January 1, 2013. The Company does not anticipate that this amendment will have a material impact on its consolidated financial statements. In February 2013, the FASB issued ASU No. 2013-02, Comprehensive Income (Topic 220)—Reporting Amounts Reclassified Out of Accumulated Other Comprehensive Income (ASU 2013-02). The ASU adds new disclosure requirements for items reclassified out of accumulated other comprehensive income (“AOCI”) and is intended to help entities improve the transparency of changes in other comprehensive income and items reclassified out of AOCI in their financial statements. The new disclosure requirements became effective for the Company for all interim and annual financial statement reporting periods beginning after December 15, 2012. The adoption of ASU 2013-02 did not change the recognition or measurement of net income or accumulated other comprehensive income.

Note 3 - Merger (Tables)

12 Months Ended

Jun. 30, 2013

Business Combinations [Abstract]

Schedule of Stockholders Equity [Table Text Block]

	No. of Shares
Ex-Nabi stockholders		4,720,999
Ex-Biota Holdings Limited stockholders		23,416,347
Total		28,137,346

Schedule of Business Acquisitions, by Acquisition [Table Text Block]

Number of shares issued to Nabi stockholders		4,720,999
Fair value per share, using the volume weighted share price on November 9, 2012	$	4.0168
Implied purchase consideration (in millions)	$	19.0

Number of stock options outstanding to former Nabi employees		508,918
Fair value per option	$	0.456
Implied purchase consideration (in millions)	$	0.2

Total implied purchase consideration (in millions)	$	19.2

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

Cash	$	32.7
Accrual for severance obligations and employee benefits		(5.0	)
Accounts payable		(0.7	)
Net cash received	$	27.0

Excess of net assets acquired over total fair value purchase consideration/gain recorded on merger	$	7.8

Business Acquisition, Pro Forma Information [Table Text Block]

	As of June 30,
	2013			2012

Pro forma net revenue	$	34.9		$	23.6
Pro forma net loss		(15.2	)		(24.3	)

Pro forma basic loss per share		(0.54	)		(1.07	)

Note 4 - Financial Instruments (Tables)

12 Months Ended

Jun. 30, 2013

Fair Value, by Balance Sheet Grouping [Table Text Block]

	As of June 30,
	2013		2012

Financial assets:
Cash and cash equivalents	$	66.8	$	53.8
Accounts receivable		11.0		6.0
Total financial assets		77.8		59.8

Financial liabilities:
Accounts payable		4.4		2.9
Total financial liabilities		4.4		2.9

Net financial assets	$	73.4	$	56.9

Note 5 - Property and Equipment (Tables)

12 Months Ended

Jun. 30, 2013

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

	As of June 30,
	2013			2012

Property and equipment	$	6.3		$	7.0
Leasehold improvements		6.8			7.0

Total Property and equipment		13.1			14.0
Accumulated depreciation		(9.4	)		(9.1	)

Property and equipment, net	$	3.7		$	4.9

Note 6 - Intangible Assets (Tables)

12 Months Ended

Jun. 30, 2013

Schedule of Finite-Lived Intangible Assets [Table Text Block]

	As of June 30,
	2013			2012

Royalty prepayment	$	12.8		$	14.0
Computer software		1.6			1.6

Total intangible assets		14.4			15.6
Accumulated depreciation		(13.8	)		(13.8	)

Intangible assets, net	$	0.6		$	1.8

Note 7 - Accrued and Other Current Liabilities (Tables)

12 Months Ended

Jun. 30, 2013

Schedule of Accrued Liabilities [Table Text Block]

	As of June 30,
	2013		2012

Legal, tax and accounting fees	$	0.4	$	0.9
Salary and related costs		2.1		2.7
Research and development materials and services		5.4		2.5
Other accrued expenses		0.3		-
Total accrued expenses	$	8.2	$	6.1

Note 8 - Commitments and Contingent Liabilities (Tables)

12 Months Ended

Jun. 30, 2013

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

2014	$	0.5
2015		0.3
2016		0.3
2017		0.2
2018		0.1
Thereafter		0.1

Total minimum lease payments	$	1.5

Note 9 - Income Taxes (Tables)

12 Months Ended

Jun. 30, 2013

Income Tax Disclosure [Abstract]

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

	As of June 30,
	2013			2012

Deferred tax assets:
Foreign net operating loss carryforwards	$	18.2		$	21.1
Amortization		0.8			0.9
Depreciation		0.2			0.1
Accrued compensated-related costs		0.4			1.8
Other		3.7			0.4
		23.3			24.3
Deferred tax liabilities:
Royalties		(1.9	)		(1.9	)
		(1.9	)		(1.9	)

Total deferred tax assets		21.4			22.4
Valuation allowance		(21.4	)		(21.1	)

Net deferred tax assets	$	-		$	1.3

Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]

	Years Ended June 30,
	2013			2012			2011

United States	$	6.7		$	-		$	-
Foreign		(15.3	)		(19.7	)		(26.1	)

Total	$	(8.6	)	$	(19.7	)	$	(26.1	)

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

	Years Ended June 30,
	2013		2012			2011
Current:
Federal	$	-	$	-		$	-
State		-		-			-
Foreign		0.1		(0.3	)		(1.2	)
		0.1		(0.3	)		(1.2	)
Deferred:
Federal		-		-			-
State		-		-			-
Foreign		-		(0.2	)		0.4
		-		(0.2	)		0.4
Total Tax Expense	$	0.1	$	(0.5	)	$	(0.8	)

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

	Years Ended June 30,
	2013			2012			2011
Income tax expense (benefit) at federal statutory rate	$	(3.3	)	$	(6.9	)	$	(9.2	)
State and local income taxes, net of federal benefit		0.3			-			-
Foreign tax rate differential		1.3			0.9			0.5
Change in valuation allowance (Net of Nabi merger)		4.2			2.8			9.8
Gain on merger		(3.0	)		-			-
Research and development expenses		1.1			2.9			(1.3	)
Research and development tax credits		(1.1	)		(0.3	)		(1.1	)
Employee stock options		0.5			0.2			0.1
Other		0.1			(0.1	)		0.4
Income tax expense (benefit)	$	0.1		$	(0.5	)	$	(0.8	)

Note 10 - Share Based Compensation (Tables)

12 Months Ended

Jun. 30, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

	Number of Options
Options	Biota Holdings Limited			Nabi			Biota Pharmaceuticals, Inc.

Outstanding at June 30, 2012		6,182,853			3,665,201			-
Granted		686,365			-			-
Exercised		(413,335	)		-			-
Forfeited		-			(20,000	)		-
Expired		(601	)		(591,485	)		-

		6,455,282			3,053,716			-
Adjustment for Consolidation of shares					(2,544,798	)		-
Vested and exercised upon merger		(6,455,282	)		-			-
Balance on November 8, 2012 (date of merger)		-			508,918			-

Post-merger transactions:
Granted		-			-			1,166,590
Expired		-			(16,979	)		-

Outstanding at June 30, 2013		-			491,939			1,166,590

Exercisable at June 30, 2013		-			491,939			-

Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]

	Number of Awards
Awards	Nabi			Biota Pharmaceuticals, Inc.

Unvested at June 30, 2012		196,254			-
Vested and shares issued		(196,254	)		-

Balance on November 8, 2012 (date of merger)		-			-

Post-merger transactions:
Granted		-			241,083
Vested		-			(71,661	)

Outstanding at June 30, 2013	Nil				169,422

Note 12 - Net Loss Per Share (Tables)

12 Months Ended

Jun. 30, 2013

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Year Ended June 30,
	2013			2012			2011

Net loss (in millions)	$	(8.7	)	$	(19.2	)	$	(25.4	)
Weighted-average shares outstanding		28,217,515			181,775,444			180,610,151
Weighted- average shares outstanding adjusted using exchange ratio used to compute basic earnings per share		-			22,713,566			22,567,958
Shares used to compute diluted earnings per share		28,217,515			22,713,566			22,567,958
Basic loss per share	$	(0.31	)	$	(0.85	)	$	(1.12	)
Diluted loss per share	$	(0.31	)	$	(0.85	)	$	(1.12	)
Number of antidilutive stock options excluded from computation		-			-			1,658,529

Note 14 - Licences, Royalty Collaborative and Contractual Arrangements (Tables)

12 Months Ended

Jun. 30, 2013

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Years Ended June 30,
	2013		2012		2011
Royalty revenue – Relenza^®	$	2.6	$	4.4	$	6.6
– Inavir^®		4.2		4.5		2.9
Commercial milestone – Inavir^®		2.8		-		-
Revenue from services		24.0		11.5		3.0
Total revenue	$	33.6	$	20.4	$	12.5

Note 15 - Quarterly Financial Information (Unaudited) (Tables)

12 Months Ended

Jun. 30, 2013

Quarterly Financial Information Disclosure [Abstract]

Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]

	Quarter Ended
	6/30/2013			3/31/2013		12/31/2012		9/30/2012
Revenues	$	9.3		$	12.5	$	10.4	$	1.4
Operating expenses		7.7			4.1		7.1		1.5
Net (loss) income		(6.5	)		0.2		4.8		(7.2	)
Net (loss) income per share (1):
Basic	$	(0.23	)	$	0.01	$	0.17	$	(0.32	)
Diluted	$	(0.23	)	$	0.01	$	0.17	$	(0.32	)

	Quarter Ended
	6/30/2012			3/31/2012			12/31/2011			9/30/2011
Revenues	$	7.1		$	7.1		$	2.1		$	4.1
Operating expenses		3.8			1.8			2.9			1.4
Net loss		(5.9	)		(2.0	)		(7.1	)		(4.2	)
Net loss per share (1):
Basic	$	(0.26	)	$	(0.09	)	$	(0.31	)	$	(0.18	)
Diluted	$	(0.26	)	$	(0.09	)	$	(0.31	)	$	(0.18	)

Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22580-107794

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6510796

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e765-108305

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22499-107794

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22583-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e725-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 01
-Paragraph b
-Subparagraph 6
-Article 10

+ Details

Note 1 - Company Overview (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
Note 1 - Company Overview (Details) - USD ($) $ in Millions	Mar. 31, 2011	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011	Nov. 08, 2012
Biota Holdings Limited [Member]
Note 1 - Company Overview (Details) [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired					83.00%
Nabi [Member]
Note 1 - Company Overview (Details) [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired					17.00%
Barda [Member]
Note 1 - Company Overview (Details) [Line Items]
Contracts Revenue (in Dollars)				$ 231.2
Contracts Revenue (in Dollars)	$ 231.2	$ 24.0	$ 11.5	$ 3.0

Note 2 - Basis of Presentation (Details)	12 Months Ended
Note 2 - Basis of Presentation (Details)	Jun. 30, 2013
Minimum [Member]
Note 2 - Basis of Presentation (Details) [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
Note 2 - Basis of Presentation (Details) [Line Items]
Property, Plant and Equipment, Useful Life	10 years

Note 3 - Merger (Details) - Nabi [Member]	12 Months Ended
Note 3 - Merger (Details) - Nabi [Member]	Jun. 30, 2013 $ / shares
Minimum [Member]
Note 3 - Merger (Details) [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price (in Dollars per share)	$ 11.34
Fair Value Assumptions, Expected Volatility Rate	78.79%
Fair Value Assumptions, Risk Free Interest Rate	0.12%
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term	109 days
Maximum [Member]
Note 3 - Merger (Details) [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price (in Dollars per share)	$ 99.91
Fair Value Assumptions, Expected Volatility Rate	99.62%
Fair Value Assumptions, Risk Free Interest Rate	0.87%
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term	6 years 36 days

Note 3 - Merger (Details) - Issued Share Capital	Jun. 30, 2013 shares
Nabi [Member]
No. of Shares
Number of Shares on Issue	4,720,999
Biota Holdings Limited [Member]
No. of Shares
Number of Shares on Issue	23,416,347
Number of Shares on Issue	28,137,346

Note 3 - Merger (Details) - Fair Value Purchase Consideration $ / shares in Units, $ in Millions	12 Months Ended
	Jun. 30, 2013 USD ($) $ / shares shares
Employee Stock Option [Member] \| Nabi
Business Acquisition [Line Items]
Fair Value Purchase Consideration \| $	$ 0.2
Nabi \| Stock Shares
Business Acquisition [Line Items]
Fair Value Purchase Consideration \| $	$ 19.0
Nabi
Business Acquisition [Line Items]
Number of shares issued to Nabi stockholders (in Shares) \| shares	4,720,999
Fair value per share, using the volume weighted share price on November 9, 2012 (in Dollars per share) \| $ / shares	$ 4.0168
Fair Value Purchase Consideration \| $	$ 19.2
Number of stock options outstanding to former Nabi employees (in Shares) \| shares	508,918
Fair value per option (in Dollars per share) \| $ / shares	$ 0.456
Fair value per option (in Dollars per share) \| $ / shares	$ 2.39

Note 3 - Merger (Details) - Net Assets Acquired $ in Millions	12 Months Ended
	Jun. 30, 2013 USD ($)
Biota [Member]
Note 3 - Merger (Details) - Net Assets Acquired [Line Items]
Cash	$ 32.7
Accrual for severance obligations and employee benefits	(5.0)
Accounts payable	(0.7)
Net cash received	27.0
Excess of net assets acquired over total fair value purchase consideration/gain recorded on merger	7.8
Excess of net assets acquired over total fair value purchase consideration/gain recorded on merger	$ 7.8

Note 3 - Merger (Details) - Business Acquisition Pro Forma Information - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Business Acquisition Pro Forma Information [Abstract]
Pro forma net revenue	$ 34.9	$ 23.6
Pro forma net loss	$ (15.2)	$ (24.3)
Pro forma basic loss per share (in Dollars per share)	$ (0.54)	$ (1.07)

Note 4 - Financial Instruments (Details) - Financial Instruments - USD ($) $ in Millions	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2010
Financial assets:
Cash and cash equivalents	$ 66.8	$ 53.8	$ 74.2	$ 89.8
Accounts receivable	11.0	6.0
Total financial assets	77.8	59.8
Financial liabilities:
Accounts payable	4.4	2.9
Total financial liabilities	4.4	2.9
Net financial assets	$ 73.4	$ 56.9

Note 5 - Property and Equipment (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011
Property, Plant and Equipment [Abstract]
Depreciation	$ 1.8	$ 1.8	$ 1.7

Note 5 - Property and Equipment (Details) - Property and Equipment - USD ($) $ in Millions	Jun. 30, 2013	Jun. 30, 2012
Property and Equipment [Abstract]
Property and equipment	$ 6.3	$ 7.0
Leasehold improvements	6.8	7.0
Total Property and equipment	13.1	14.0
Accumulated depreciation	(9.4)	(9.1)
Property and equipment, net	$ 3.7	$ 4.9

Note 6 - Intangible Assets (Details) - Scenario, Forecast [Member] $ in Millions	Jun. 30, 2012 USD ($)
June 30, 2014 [Member]
Note 6 - Intangible Assets (Details) [Line Items]
Amortization	$ 0.5
June 30, 2015 [Member]
Note 6 - Intangible Assets (Details) [Line Items]
Amortization	$ 0.1

Note 6 - Intangible Assets (Details) - Intangible Assets - USD ($) $ in Millions	Jun. 30, 2013	Jun. 30, 2012
Intangible Assets [Abstract]
Royalty prepayment	$ 12.8	$ 14.0
Computer software	1.6	1.6
Total intangible assets	14.4	15.6
Accumulated depreciation	(13.8)	(13.8)
Intangible assets, net	$ 0.6	$ 1.8

Note 7 - Accrued and Other Current Liabilities (Details) - Accrued and Other Current Liabilities - USD ($) $ in Millions	Jun. 30, 2013	Jun. 30, 2012
Accrued and Other Current Liabilities [Abstract]
Legal, tax and accounting fees	$ 0.4	$ 0.9
Salary and related costs	2.1	2.7
Research and development materials and services	5.4	2.5
Other accrued expenses	0.3
Total accrued expenses	$ 8.2	$ 6.1

Note 8 - Commitments and Contingent Liabilities (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2006
Rent Expense [Member]
Note 8 - Commitments and Contingent Liabilities (Details) [Line Items]
Leasehold Improvements, Gross	$ 0.1
Leasehold Improvements, Gross	6.8	$ 7.0
Security Deposit	0.1
Operating Leases, Rent Expense	1.1	0.8	$ 0.8
Revenue from Grants	$ 0.6	$ 0.6
Grants Receivable			$ 2.9	$ 8.5

Note 8 - Commitments and Contingent Liabilities (Details) - Future Minimum Lease Payments $ in Millions	Jun. 30, 2013 USD ($)
Future Minimum Lease Payments [Abstract]
2014	$ 0.5
2015	0.3
2016	0.3
2017	0.2
2018	0.1
Thereafter	0.1
Total minimum lease payments	$ 1.5

Note 9 - Income Taxes (Details) - USD ($) $ in Millions	Jun. 30, 2013	Jun. 30, 2012
Australaa [Member]
Note 9 - Income Taxes (Details) [Line Items]
Operating Loss Carryforwards	$ 44.6
United Kingdom [Member]
Note 9 - Income Taxes (Details) [Line Items]
Operating Loss Carryforwards	23.9
Deferred Tax Assets, Valuation Allowance	21.4	$ 21.1
Operating Loss Carryforwards	$ 0.1

Note 9 - Income Taxes (Details) - Summary of Deferred Tax Assets and Liabilities - USD ($) $ in Millions	Jun. 30, 2013	Jun. 30, 2012
Deferred tax assets:
Foreign net operating loss carryforwards	$ 18.2	$ 21.1
Amortization	0.8	0.9
Depreciation	0.2	0.1
Accrued compensated-related costs	0.4	1.8
Other	3.7	0.4
	23.3	24.3
Deferred tax liabilities:
Royalties	(1.9)	(1.9)
	(1.9)	(1.9)
Total deferred tax assets	21.4	22.4
Valuation allowance	$ (21.4)	(21.1)
Net deferred tax assets		$ 1.3

Note 9 - Income Taxes (Details) - Summary of Income Before Taxes, Domestic and Foreign - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011
Summary of Income Before Taxes, Domestic and Foreign [Abstract]
United States	$ 6.7
Foreign	(15.3)	$ (19.7)	$ (26.1)
Total	$ (8.6)	$ (19.7)	$ (26.2)

Note 9 - Income Taxes (Details) - Components of Income Tax Expense (Benefit) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011
Current:
Federal	$ 0.0
State	0.0
Foreign	0.1	$ (0.3)	$ (1.2)
	0.1	(0.3)	(1.2)
Deferred:
Federal	0.0
State	0.0
Foreign	0.0	(0.2)	0.4
		(0.2)	0.4
Total Tax Expense	$ 0.1	$ (0.5)	$ (0.8)

Note 9 - Income Taxes (Details) - Reconciliation of Effective Tax Rate - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011
Reconciliation of Effective Tax Rate [Abstract]
Income tax expense (benefit) at federal statutory rate	$ (3.3)	$ (6.9)	$ (9.2)
State and local income taxes, net of federal benefit	0.3
Foreign tax rate differential	1.3	0.9	0.5
Change in valuation allowance (Net of Nabi merger)	4.2	2.8	9.8
Gain on merger	(3.0)
Research and development expenses	1.1	2.9	(1.3)
Research and development tax credits	(1.1)	(0.3)	(1.1)
Employee stock options	0.5	0.2	0.1
Other	0.1	(0.1)	0.4
Income tax expense (benefit)	$ 0.1	$ (0.5)	$ (0.8)

Note 10 - Share Based Compensation (Details) - $ / shares		12 Months Ended
	Nov. 08, 2012	Jun. 30, 2013
Nabi [Member] \| Minimum [Member]
Note 10 - Share Based Compensation (Details) [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit (in Dollars per share)	$ 11.22
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term		109 days
Nabi [Member] \| Maximum [Member]
Note 10 - Share Based Compensation (Details) [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term		6 years 36 days
Nabi \| Maximum [Member]
Note 10 - Share Based Compensation (Details) [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit (in Dollars per share)	$ 99.94

Note 10 - Share Based Compensation (Details) - Summary of Option Activity Under Stock Compensation Plans - shares	4 Months Ended	8 Months Ended
	Nov. 08, 2012	Jun. 30, 2013
Biota Holdings Limited [Member] \| Pre Merger [Member]
Note 10 - Share Based Compensation (Details) - Summary of Option Activity Under Stock Compensation Plans [Line Items]
Balance Outstanding	6,455,282
Post-merger transactions:
Granted	686,365
Expired	(601)
Nabi \| Pre Merger [Member]
Note 10 - Share Based Compensation (Details) - Summary of Option Activity Under Stock Compensation Plans [Line Items]
Balance Outstanding	3,053,716
Post-merger transactions:
Expired	(591,485)
Nabi \| Post Merger [Member]
Note 10 - Share Based Compensation (Details) - Summary of Option Activity Under Stock Compensation Plans [Line Items]
Balance Outstanding	508,918
Post-merger transactions:
Expired		(16,979)
Post Merger [Member]
Post-merger transactions:
Granted		1,166,590

Note 10 - Share Based Compensation (Details) - Summary of Restricted Stock Awards - shares	4 Months Ended	8 Months Ended
	Nov. 08, 2012	Jun. 30, 2013	Jun. 30, 2012
Nabi [Member]
Note 10 - Share Based Compensation (Details) - Summary of Restricted Stock Awards [Line Items]
Unvested at June 30, 2012			196,254
Vested	(196,254)
Post-merger transactions:
Outstanding at June 30, 2013
Biota [Member]
Note 10 - Share Based Compensation (Details) - Summary of Restricted Stock Awards [Line Items]
Vested		(71,661)
Post-merger transactions:
Granted		241,083
Outstanding at June 30, 2013		169,422

Note 11 - Retirement Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011
Non-US Employees [Member]
Note 11 - Retirement Benefits (Details) [Line Items]
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	9.00%
US Employees [Member]
Note 11 - Retirement Benefits (Details) [Line Items]
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	4.00%
Defined Benefit Plan, Contributions by Employer	$ 1.1	$ 1.1	$ 1.0

Note 12 - Net Loss Per Share (Details) - Computation of Historical Basic and Diluted Net Income (Loss) Per Share - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011
Prior to Adjustments [Member]
Note 12 - Net Loss Per Share (Details) - Computation of Historical Basic and Diluted Net Income (Loss) Per Share [Line Items]
Weighted average shares outstanding	28,217,515	181,775,444	180,610,151
Adjusted Using Exchange Ratio [Member]
Note 12 - Net Loss Per Share (Details) - Computation of Historical Basic and Diluted Net Income (Loss) Per Share [Line Items]
Weighted average shares outstanding		22,713,566	22,567,958
Basic loss per share (in Dollars per share)	$ (0.31)	$ (0.85)	$ (1.12)
Diluted loss per share (in Dollars per share)	$ (0.31)	$ (0.85)	$ (1.12)
NetIncomeLoss	$ (8.7)	$ (19.2)	$ (25.4)
Weighted average shares outstanding	28,217,515	22,713,566	22,567,958
Shares used to compute diluted earnings per share	28,217,515	22,713,566	22,567,958
Basic loss per share (in Dollars per share)	$ (0.31)	$ (0.85)	$ (1.12)
Diluted loss per share (in Dollars per share)	$ (0.31)	$ (0.85)	$ (1.12)
Number of antidilutive stock options excluded from computation			1,658,529

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Note 13 - Research and Development Credit (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011
Research and Development [Abstract]
Research and Development Credit	$ 4.4	$ 0.0	$ 0.0

Note 14 - Licences, Royalty Collaborative and Contractual Arrangements (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Mar. 31, 2011	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011
GSK \| Major Countries
Note 14 - Licences, Royalty Collaborative and Contractual Arrangements (Details) [Line Items]
Royalty Payment Percentage		7.00%
GSK \| Australia, New Zealand, South Africa and Indonesia
Note 14 - Licences, Royalty Collaborative and Contractual Arrangements (Details) [Line Items]
Royalty Payment Percentage		10.00%
Daiichi Sankyo
Note 14 - Licences, Royalty Collaborative and Contractual Arrangements (Details) [Line Items]
Royalty Payment Percentage		4.00%
BARDA
Note 14 - Licences, Royalty Collaborative and Contractual Arrangements (Details) [Line Items]
Contracts Revenue (in Dollars)		$ 34.1
Contract Term	5 years
Contracts Revenue (in Dollars)	$ 231.2	$ 24.0	$ 11.5	$ 3.0

Note 14 - Licences, Royalty Collaborative and Contractual Arrangements (Details) - Components of Revenues from Royalties, Collaborative and Contractual Agreements - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Mar. 31, 2011	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011
Relenza [Member]
Segment Reporting Information [Line Items]
Royalty Revenue		$ 2.6	$ 4.4	$ 6.6
Inavir [Member]
Segment Reporting Information [Line Items]
Royalty Revenue		4.2	4.5	2.9
Commercial milestone – Inavir®		2.8
Royalty Revenue		9.6	8.8	9.5
Revenue from services	$ 231.2	24.0	11.5	3.0
Total revenue		$ 33.6	$ 20.4	$ 12.5

Note 15 - Quarterly Financial Information (Unaudited) (Details) - Consolidated Quarterly Financial Information - USD ($)
$ / shares in Units, $ in Millions

3 Months Ended

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2011

Sep. 30, 2011

Fourth Quarter [Member]

$ 9.3

$ 7.1

7.7

3.8

$ (6.5)

$ (5.9)

^[1]

$ (0.23)

$ (0.26)

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

^[1]

$ (0.23)

$ (0.26)

Third Quarter [Member]

$ 12.5

$ 7.1

4.1

1.8

$ 0.2

$ (2.0)

^[1]

$ 0.01

$ (0.09)

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

^[1]

$ 0.01

$ (0.09)

Second Quarter [Member]

$ 10.4

$ 2.1

7.1

2.9

$ 4.8

$ (7.1)

^[1]

$ 0.17

$ (0.31)

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

^[1]

$ 0.17

$ (0.31)

First Quarter [Member]

$ 1.4

$ 4.1

1.5

1.4

$ (7.2)

$ (4.2)

^[1]

$ (0.32)

$ (0.18)